Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...
To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback